Division of Memorial Sloan Kettering Cancer Center
Latest From Sloan-Kettering Institute
With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.
Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.
With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.